These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7411850)

  • 1. [Studies on the stability of aclacinomycin hydrochloride. I. Stability of solution of aclacinomycin hydrochloride (author's transl)].
    Mori S; Shindo N; Miura H; Oki T; Inui T
    Jpn J Antibiot; 1980 Apr; 33(4):466-71. PubMed ID: 7411850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosynthesis of anthracycline antibiotics by Streptomyces galilaeus. I. Glycosidation of various anthracyclinones by an aclacinomycin-negative mutant and biosynthesis of aclacinomycins from aklavinone.
    Oki T; Yoshimoto A; Matsuzawa Y; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1980 Nov; 33(11):1331-40. PubMed ID: 6941952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoassay for aclacinomycin A.
    Matsuzawa Y; Kiyosaki T; Oki T; Takeuchi T; Umezawa H
    Gan; 1982 Apr; 73(2):229-33. PubMed ID: 6956531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma kinetics of aclacinomycin A and its major metabolites in man.
    Egorin MJ; Van Echo D; Fox BM; Whitacre M; Bachur NR
    Cancer Chemother Pharmacol; 1982; 8(1):41-6. PubMed ID: 6954015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of anthracycline antitumor agents in four infusion fluids.
    Poochikian GK; Cradock JC; Flora KP
    Am J Hosp Pharm; 1981 Apr; 38(4):483-6. PubMed ID: 6945043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label.
    Sohda M; Fujiwara K; Saikusa H; Kitagawa T; Nakamura N; Hara K; Tone H
    Cancer Chemother Pharmacol; 1985; 14(1):53-8. PubMed ID: 3917377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anthracycline metabolites from mutant strains of Streptomyces galilaeus MA144-M1. I. Isolation and characterization of various blocked mutants.
    Yoshimoto A; Matsuzawa Y; Oki T; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1981 Aug; 34(8):951-8. PubMed ID: 6947976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological cross-reactivities of various anthracycline antibiotics against aclacinomycin A antisera.
    Matsuzawa Y; Kiyosaki T; Yoshimoto A; Ishikura T; Takeuchi T; Umezawa H
    J Pharmacobiodyn; 1982 Nov; 5(11):886-92. PubMed ID: 6962833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies of aclacinomycin A (ACM).
    Majima H; Ohta K
    Biomed Pharmacother; 1987; 41(5):233-7. PubMed ID: 3311189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiochemical properties and stability of aclacinomycin A hydrochloride.
    Mori S; Ogasawara T; Nishimura M; Miura H; Goto S; Oki T; Inui T
    Jpn J Antibiot; 1980 May; 33(5):618-22. PubMed ID: 6933235
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduction of anthracycline glycoside by NADPH--cytochrome P-450 reductase.
    Komiyama T; Oki T; Inui T; Takeuchi T; Umezawa H
    Gan; 1979 Aug; 70(4):403-10. PubMed ID: 41795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of cinerulose in aclacinomycin-A by soluble and microsomal cinerulose reductases.
    Komiyama T; Oki T; Inui T; Takeuchi T; Umezawa H
    Gan; 1979 Aug; 70(4):395-401. PubMed ID: 41794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
    Warrell RP
    Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer.
    Feng C; Li X; Dong C; Zhang X; Zhang X; Gao Y
    Drug Des Devel Ther; 2015; 9():4613-20. PubMed ID: 26316700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental studies on aclacinomycin.
    Tone H; Nishida H; Takeuchi T; Umezawa H
    Drugs Exp Clin Res; 1985; 11(1):9-15. PubMed ID: 2424701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravesical instillation therapy of aclacinomycin-A (ACM) for superficial bladder tumor].
    Noguchi S; Kubota Y; Shuin T; Miura T; Moriyama M; Sakuramoto T; Oshima H
    Hinyokika Kiyo; 1984 Sep; 30(9):1153-8. PubMed ID: 6596878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aclacinomycin on cell survival and cell cycle progression of cultured mammalian cells.
    Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
    Cancer Res; 1981 Jul; 41(7):2728-37. PubMed ID: 6166368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor anthracycline antibiotics, aclacinomycin A and analogues. I. Taxonomy, production, isolation and physicochemical properties.
    Oki T; Kitamura I; Yoshimoto A; Matsuzawa Y; Shibamoto N; Ogasawara T; Inui T; Takamatsu A; Takeuchi T; Masuda T; Hamada M; Suda H; Ishizuka M; Sawa T; Umezawa H
    J Antibiot (Tokyo); 1979 Aug; 32(8):791-800. PubMed ID: 500500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacies of aclacinomycin A by oral administration.
    Tsukagoshi S; Tsuruo T; Yamori T; Iida H; Naganuma K; Sakurai Y
    J Pharmacobiodyn; 1980 Oct; 3(10):532-6. PubMed ID: 6937651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.